Related Experiment Video
Updated: May 17, 2026
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
Published on: March 25, 2014
A cell-based MHC stabilization assay for the detection of peptide binding to the canine classical class I molecule,
Peter Ross1, Jennifer C Holmes, Gregory S Gojanovich
1Immunology Program, Department of Clinical Sciences, North Carolina State University College of Veterinary Medicine, Raleigh, NC 27607, USA.
Insights
Discovering CD8+ T-cell epitopes in dogs is challenging. Researchers adapted a cell-based assay using canine MHC class I alleles to improve the identification of immunodominant CTL epitopes.
Area of Science:
- Immunology
- Veterinary Science
- Molecular Biology
Background:
- Identifying immunodominant cytotoxic T-lymphocyte (CTL) epitopes is crucial for understanding CD8+ T-cell responses.
- Current methods for epitope discovery are limited by the vast number of potential peptide candidates within antigens.
- In silico prediction of peptide-MHC binding is a common first step but requires experimental validation.
Purpose of the Study:
- To develop a novel assay for identifying canine CTL epitopes.
- To adapt an existing peptide-MHC stabilization assay for use with canine major histocompatibility complex (MHC) class I alleles.
- To assess the feasibility of using engineered cell lines for canine epitope discovery.
Main Methods:
- Transfection of the canine MHC class I allele DLA-88*50801 into the TAP-deficient RMA-S cell line.
- Generation of a specific cell line clone (BARC3) expressing the canine MHC molecule.
- Validation of the assay by assessing the stabilization of surface MHC molecules upon binding of motif-matched versus motif-mismatched peptides.
Main Results:
- Successful expression of a functional canine MHC class I molecule (DLA-88*50801) in the engineered RMA-S cells.
- The assay demonstrated the ability to differentiate between peptides based on their binding affinity to the canine MHC molecule.
- Peptide-MHC complex stability on the cell surface correlated with predicted binding motifs.
Conclusions:
- Transfected RMA-S cells expressing canine MHC class I alleles can serve as a valuable tool for CTL epitope discovery in dogs.
- This approach offers a more efficient method for validating predicted epitopes compared to traditional methods.
- The developed assay has significant potential for advancing canine immunology research and vaccine development.
Abstract:
Identifying immunodominant CTL epitopes is essential for studying CD8+ T-cell responses in populations, but remains difficult, as peptides within antigens typically are too numerous for all to be synthesized and screened. Instead, to facilitate discovery, in silico scanning of proteins for sequences that match the motif, or binding preferences, of the restricting MHC class I allele - the largest determinant of immunodominance - can be used to predict likely candidates. The high false positive rate with this analysis ideally requires binding confirmation, which is obtained routinely by an assay using cell lines such as RMA-S that have defective transporter associated with antigen processing (TAP) machinery, and consequently, few surface class I molecules. The stabilization and resultant increased life-span of peptide-MHC complexes on the cell surface by the addition of true binders validates their identity. To determine whether a similar assay could be developed for dogs, we transfected a prevalent class I allele, DLA-88*50801, into RMA-S. In the BARC3 clone, the recombinant heavy chain was associated with murine β2-microglobulin, and importantly, could differentiate motif-matched and -mismatched peptides by surface MHC stabilization. This work demonstrates the potential to use RMA-S cells transfected with canine alleles as a tool for CTL epitope discovery in this species.
